Emergent BioSolutions Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm one of the Biotech Analysts at JPMorgan. And we're continuing the 2020 healthcare conference with Emergent BioSolutions. We're going to do a Q&A session with the management team right after this. It's just down the hall in the Yorkshire room. But for the presentation, I'm going to turn it over to the company's President and CEO, Bob Kramer.
Thanks, Jess. Good morning, everybody. A special thank you to JPMorgan as well as to Jess who have supported our company for a long time, first going public in 2006, and I've appreciated and enjoyed Jess' coverages for the last several years.
So this morning, I'm going to do a couple of things. I'm going to go through an overview of Emergent BioSolutions, who we are as a company, what we focus on, and hopefully give you a better appreciation for what differentiates us from most other companies that you'll
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
